Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Cytomx Therapeutics Inc | 57 |
| 2 | Council of Scientific and Industrial Research CSIR | 12 |
| 3 | Oncternal Therapeutics Inc | 10 |
| 4 | University of Tennessee Research Foundation | 10 |
| 5 | Massachusetts Institute of Technology | 9 |
| 6 | Memorial Sloan Kettering Cancer Center | 9 |
| 7 | Eidgenoessische Technische Hochschule Zurich ETHZ | 8 |
| 8 | Dana Farber Cancer Institute Inc | 7 |
| 9 | Columbia University in the City of New York | 6 |
| 10 | AOP Orphan Pharmaceuticals AG | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 204 |
| 2 | A61K | Medicinal preparations | 197 |
| 3 | C07K | Peptides | 120 |
| 4 | C07D | Heterocyclic compounds | 87 |
| 5 | C07C | Acyclic and carbocyclic compounds | 42 |
| 6 | C07F | Organometallic compounds | 34 |
| 7 | C07B | General methods of organic chemistry | 19 |
| 8 | G01N | Investigating / analysing materials | 17 |
| 9 | C12N | Microorganisms, enzymes | 15 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 14 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Joëlle Dubois | Institut de Chimie des Substances Naturelles | 7 |
| 2 | Alina Ghinet | Université de Lille | 6 |
| 3 | Benoı̂t Rigo | Université de Lille | 6 |
| 4 | Amaury Farce | Université de Lille | 5 |
| 5 | Concepción Álvarez | Universidad de Salamanca | 4 |
| 6 | Elena Bîcu | Alexandru Ioan Cuza University | 4 |
| 7 | Ernest Hamel | National Institutes of Health | 4 |
| 8 | Manuel Medarde | Universidad de Salamanca | 4 |
| 9 | Philippe Gautret | Université de Lille | 4 |
| 10 | Rafael Peláez | Universidad de Salamanca | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Synthesis, biological evaluation, and molecular docking analysis of phenstatin based indole linked chalcones as anticancer agents and tubulin polymerization inhibitors | 2020 | 101 | Synthesis and biological activity |
| Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance | 2017 | 28 | Metal complexes synthesis and properties |
| Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors | 2016 | 21 | Synthesis and biological activity |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of this compound?
Which organization holds the most patents related to this compound?
What are the primary research areas covered by patents for this compound?
What biological activities has this compound been investigated for?
How has patent activity for this compound trended in recent years?